Pharmaceutical giant AbbVie is advancing its neuroscience portfolio by acquiring Gilgamesh Pharmaceuticals’ experimental psychedelic compound, bretisilocin, for up to $1.2 billion including upfront and milestone payments. This acquisition follows a prior collaboration and reflects growing industry interest in psychedelic therapies for major depressive disorder. Gilgamesh will spin off remaining programs into a new company. AbbVie’s move underscores its strategic focus despite recent challenges in other neuropsychiatric assets.